Depression in Alzheimer's Disease-2 (DIADS-2)
Alzheimer's Disease, Depression
About this trial
This is an interventional treatment trial for Alzheimer's Disease focused on measuring Alzheimer's disease, Depression
Eligibility Criteria
Inclusion: Ability of the participant, caregiver or surrogate to provide written informed consent. Dementia due to Alzheimer's disease Stable treatment for Alzheimer's disease Ability for the participant's caregiver to accompany the participant to study visits and participate in the study. Exclusion Presence of a brain disease that might otherwise explain the presence of dementia Clinically significant hallucinations or delusions Current treatment of antipsychotics, anticonvulsants, and other antidepressants, benzodiazepines, or other psychotropic medications Need for hospitalization or residence in a nursing facility
Sites / Locations
- University of Southern California
- Johns Hopkins Hospital
- University of Rochester
- University of Pennsylvania
- Medical University of South Carolina
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
1
2
Participants will receive sertraline at a target dose of 100mg daily.
Participants will receive placebo matched to sertraline